BCL-2 antisense therapy in patients with non-Hodgkin lymphoma
- 1 April 1997
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 349 (9059), 1137-1141
- https://doi.org/10.1016/s0140-6736(96)11103-x
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Antisense oligonucleotides: towards clinical trialsTrends in Biotechnology, 1996
- Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation StudyBlood, 1996
- Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies.Journal of Clinical Oncology, 1996
- Prognostic significance of bcl-2 protein expression in aggressive non- Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA)Blood, 1996
- Primitive human hematopoietic precursors express Bcl-x but not Bcl-2Published by American Society of Hematology ,1995
- Complement Activation and Hemodynamic Changes Following Intravenous Administration of Phosphorothioate Oligonucleotides in the MonkeyAntisense Research and Development, 1994
- Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hairCell, 1993
- Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphomaBritish Journal of Cancer, 1992
- Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell deathNature, 1990
- Reporting results of cancer treatmentCancer, 1981